TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced the publication of peer-reviewed preclinical research supporting the use of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme, one of the most aggressive forms of brain cancer. The study, conducted in collaboration with Michigan State University and published in the Journal of Functional Biomaterials, demonstrated that systemic delivery of TTX-MC138 successfully reached brain tumors in orthotopic glioblastoma models, significantly increased tumor cell apoptosis, and resulted in a statistically significant improvement in survival.
The findings further validate TransCode's TTX delivery platform and support the potential advancement of TTX-MC138 into future clinical evaluation for patients with glioblastoma, building on completed IND-enabling studies and existing Phase 1 clinical experience outside the central nervous system. This research is significant because glioblastoma remains one of the most difficult cancers to treat, with limited therapeutic options and poor survival rates despite current standard treatments.
The implications of this announcement extend beyond the immediate research findings. For patients facing glioblastoma, this represents a potential new therapeutic approach that could address the critical challenge of delivering effective treatments across the blood-brain barrier. For the oncology field, the successful systemic delivery of TTX-MC138 to brain tumors suggests broader applications for treating other central nervous system cancers and metastatic brain tumors.
TransCode Therapeutics is a clinical stage company pioneering immunoncology and RNA therapeutic treatments of high risk and advanced cancers. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors that overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. In addition, TransCode has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells.
The latest news and updates relating to RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ. BioMedWire is a specialized communications platform with a focus on the latest developments in the Biotechnology, Biomedical Sciences and Life Sciences sectors. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
